OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-03-31-accounts

Registered charity number: 1185148

Report of the Trustees and Unaudited Financial Statements for the year ended 31 March 2025

for British Lymphology Society CIO

British Lymphology Society CIO Contents of the Financial Statements for the year ended 31 March 2025

Page
Information page 1
Report of the Trustees 2
Independent Examiner's Report 9
Statement of Financial Activities 10
Balance Sheet 11
Notes to the Financial Statements 12

British Lymphology Society CIO Information Page for the year ended 31 March 2025

Registered Charity Number

1185148

Trustees

Co Chairperson - Yolande Borthwick (from November 2024) Co Chairperson - Lorraine Brown (from November 2024) Vice Chairperson - Margaret Sneddon (from November 2024) Treasurer - Peter Hooper-Smith

Trustees - Rebecca Elwell Rachael Hutton Devina Dicarlo (resigned 04/03/25) Tamara Kosevic Katie Riches Carla Zanichelli Vives

Co-opted Trustee & BLS editor Cheryl White

BLS Scientific Committee chair & Co-opted trustee

Emma Underwood

Independent Examiner

J Bardolph ACA, FCCA, BFP Accountably Ltd 1st Floor, Unit 12 Compass Point Ensign Way Hamble Southampton Hampshire SO31 4RA

1

British Lymphology Society CIO Report of the Trustees for the year ended 31 March 2025

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity registered with the Charity Commission on 3 September 2019, under registration number 1185148 and is a charitable incorporated organisation - CIO.

Risk management

The BLS maintains a proactive approach to risk through regular assessments with key stakeholders and project leads, systematically mapping potential financial, operational, regulatory, and reputational risks. Risks are evaluated in line with the Charity Commission’s Risk Management Framework (CC26), with strengthened financial controls and enhanced data and cyber security measures implemented over the past year. We are pleased to report that no incidents occurred during the year.

Policies and Procedures

The BLS has created and updated the following policies this year:

OBJECTIVES AND ACTIVITIES FOR THE PUBLIC BENEFIT

Our mission is to raise the standard of lymphoedema care across the UK. Over the past year we have continued to strengthen our role as a professional voice, shaping best practice and expanding support for those living with lymphoedema, and those who treat the condition. This report showcases our achievements and sets the stage for an exciting year ahead.

Our Priorities for Delivery

In September 2024 we approved our new strategic plan:

 Purpose: We strive for better outcomes for people with lymphoedema, to enable them to live full and active lives.

At our annual conference in October 2024, delegates were invited to provide feedback on the future direction of BLS through Stop/Start/Continue discussions, ensuring that the charity’s activities align with the needs and priorities of its members. Insights from this feedback contributed to helping us to finalise our strategic priorities for 2025-28:

2

British Lymphology Society CIO Report of the Trustees for the year ended 31 March 2025

ACHIEVEMENTS AND PERFORMANCE

As Co-Chairs of the British Lymphology Society, we are delighted to welcome you to our Annual Report for 2024–25. This year marks a particularly exciting milestone for BLS, as we celebrate 40 years since the society was established, originally as the British Lymphoedema Interest Group (BLIG). Over four decades, BLS has grown into a vibrant professional community, driving awareness, education, research, and standards of care for lymphoedema across the UK.

This year marks a particularly exciting milestone for BLS, as we celebrate 40 years since the society was established, originally as the British Lymphoedema Interest Group (BLIG). Over four decades, BLS has grown into a vibrant professional community, driving awareness, education, research, and standards of care for lymphoedema across the UK.

The past year has been full of achievement. Our Conference 2024 brought together over 200 delegates to share knowledge, launch key clinical guidance, and celebrate innovation in lymphoedema care. We have extended our engagement through Lymphaletics and youth-focused initiatives and increased participation in Lymphoedema Awareness Week, with global reach through webinars and interactive sessions. We have also strengthened our advocacy and partnerships, working with organisations such as NICE, Macmillan Cancer Support, Cancer Alliances, and the Transforming Cancer Services Team (TCST), and engaging high-profile supporters to champion research and awareness.

Looking ahead, we are particularly excited about our upcoming free “Introduction to Lymphoedema” study day, designed to provide non-specialist healthcare professionals with essential knowledge and practical skills. This, along with plans to further expand youth and family outreach and celebrate our 40th anniversary, promises to make 2025–26 another landmark year for BLS.

None of this would be possible without our dedicated trustees, staff, corporate partners, members, and supporters. Your commitment continues to drive the society forward, enabling us to innovate, extend our reach, and provide meaningful support to patients and healthcare professionals alike.

Thank you, Lorraine and Yolande

Celebrating 40 Years of BLS

2025 marks an exciting milestone for BLS, as we celebrate 40 years since the organisation was established, originally as the British Lymphoedema Interest Group (BLIG). The early pioneers who founded BLIG laid the foundations for lymphoedema treatment in the UK, and through BLIG and its successor, BLS, they built a strong professional community dedicated to improving care. Over four decades, this community has driven awareness of lymphoedema, developed structured education programmes, supported research, and established standards of treatment.

Conference 2024: Racing to Success

The BLS Conference is our largest annual event and a true highlight in the calendar, bringing together professionals, researchers, and partners from across the UK and beyond. In October 2024, over 200 delegates gathered at Chester Racecourse for an inspiring programme of education, collaboration, and innovation. Kindly sponsored by Haddenham Healthcare Ltd, Essity, Medi UK, and Juzo Ltd, the event was a real achievement for BLS and the wider lymphoedema community.

The programme had a strong focus on Breast Cancer Related Lymphoedema (BCRL), featuring international expertise from Cheryl Brunelle (Massachusetts General Hospital) and Hildegard Reul-Hirche (Brisbane), alongside leading UK speakers including Professor Amit Goyal on axillary management and breast reconstruction, and Consultant Clinical Oncologist Daljit Gahir on advances in breast cancer treatments. Additional sessions covered research into genital lymphoedema, lymphatic dysfunctions, and head and neck care, complemented by a rich poster programme and three new BLS resource launches.

Beyond the scientific sessions, delegates valued the opportunity to engage with 31 corporate partners and several patient charities at the Meet the Exhibitors Buffet. Feedback was overwhelmingly positive, with one delegate commenting it was “by far the best conference”.

3

British Lymphology Society CIO Report of the Trustees for the year ended 31 March 2025

Plans are underway for Conference 2025, which will mark a special anniversary year for BLS, set to be our most memorable celebration yet.

Key Achievements and Highlights

New Guidance and Resources

A major achievement at the 2024 Conference was the launch of several important new resources for clinicians. In partnership with Omniamed/Wounds UK, BLS introduced updated guidance on compression, alongside a new document on Manual Lymphatic Drainage (MLD) and guidance relating to heart failure. These evidence-based resources will support best practice and ensure consistency in care across services.

In addition, BLS unveiled a curated list of free training opportunities for members, bringing together high-quality courses designed to strengthen knowledge and skills. This list is now available to all members as part of our commitment to widening access to professional development.

Lymphoedema Awareness Week 2025

Lymphoedema Awareness Week (3–7 March 2025) was one of our most visible campaigns to date. The week featured a programme of webinars, strong media presence, helping to raise awareness and broaden understanding of lymphoedema among both professionals and the public.

In addition to webinars addressing general lymphoedema information and treatment we focused part of the activity on different types of cancer associated with lymphoedema this year. Key webinars broadcast included those on lymphoedema as a consequence of breast, skin and pelvic and genital cancers.

We had great support in promoting these from related charities, such as Breast Cancer Now, Pelvic Radiation Disease Association and Melanoma UK. These were useful reminders that ongoing vigilance is needed because although advances in cancer treatment have greatly improved, enabling more people to live longer, many continue to develop lymphoedema post treatment.

We were also delighted to once again be supported by the Lymphatic Education and Research Network and featured in their video promoting global awareness on World Lymphoedema Day on 6th March. Some of the webinars are available to watch on our YouTube Channel for anyone who missed them!

In addition to the events organised centrally, a key part of the success of the awareness campaign is the work of our members and corporate partners who run educational events, set up information stands in public places and share information on social media. Getting the messages out to the community and through these networks depends on the commitment and passion of so many of our members and supporters. Thank you all!

National Representation and Outreach

BLS has maintained a strong presence at key national events throughout the year, engaging healthcare professionals and promoting membership. Highlights included the National Lymphoedema Conference in London, Wound Care Today in Telford, the Society of Tissue Viability event in Bradford the Leg Club Conference in Worcester, and the online Legs Matter Roadshows. These activities provide valuable opportunities to share expertise, raise awareness of lymphoedema, and support professional development across the healthcare community.

Launch of new resources and documents

In February 2025, BLS co-chaired and represented the society at the 12[th] National Lymphoedema Conference in London. The event was a great success, sparking lively discussion and providing the platform to launch several key BLS documents, including the Lower Limb Inflammatory Pathway (formerly the Red Leg Pathway) and the Heart Failure and Compression guidance. All were met with great enthusiasm from delegates.

Alongside these launches, we also released an updated version of the BLS Limbstat limb-volume tool, further enhancing accuracy and usability for clinicians. Together, these resources strengthen day-to-day practice and reinforce BLS’s role in leading the development of evidence-based standards in lymphoedema care.

4

British Lymphology Society CIO Report of the Trustees for the year ended 31 March 2025

Lymphaletics 2024: A Family Celebration

In September 2024, the BLS Children &Young People’s Lymphoedema Special Interest Group (BLSCLSIG) hosted Lymphaletics at Bracknell Leisure Centre—a fully funded, family-centred event that brought together children and young people living with lymphoedema, along with their families. The day combined fun activities such as soft play, sports, dance workshops, and entertainment with opportunities for families to engage with industry stands, public health initiatives, and specialist clinicians.

The educational programme was equally powerful, with young people sharing their personal experiences of living with lymphoedema, and a lively Q&A led by Professor Kristiana Gordon and Professor Mortimer. The afternoon culminated in the spirited Lymphaletics games, complete with medals, certificates, and healthy lifestyle goody bags.

Feedback was unanimously positive, with the event hailed as both a community success and a meaningful source of support for families. Thanks to the dedicated team of clinicians, volunteers, and partners, including JUZO, who kindly provided uniforms, the event had a profound impact on all who attended.

Launch of first free “Introduction to Lymphoedema” study day This year, BLS launches its first free “Introduction to Lymphoedema” study day, designed specifically for non-specialist healthcare staff. The event will give an accessible overview of lymphoedema, its impact, and the principles of management, equipping participants with the knowledge to better identify and support patients.

As the first initiative of its kind from BLS, the study day reflects our commitment to widening awareness, strengthening early recognition, and ensuring more patients receive timely, effective care. We are very excited about delivering this event and hope that it will be the first of many.

Growing our Income

We are pleased to report a notable increase in sponsorship from our valued corporate partners over the past year. This growth in income has directly enabled us to broaden our reach by offering additional delegate places at our annual conference, funding our first study day and funding the lymphoedema awareness webinars, thus extending access, sharing knowledge, and deepening engagement across our community. In line with our commitment to sustainability and good governance, we carefully reinvest the majority of our income into the charity’s operations and outputs, while maintaining a prudent reserve to support long-term stability.

Trustee Recognition

We are proud to share that several of our trustees have been recognised with awards for their outstanding contributions to lymphoedema care and service. These accolades reflect not only their dedication to their roles, but also their unwavering commitment to improving outcomes for patients. The awards acknowledge a range of achievements, including exceptional impact on patient care, innovative service development, and going above and beyond in advancing the management of lymphoedema. This recognition is a testament to the passion and leadership our trustees bring to the organisation and to the wider lymphoedema community.

Congratulations to Rachael Hutton for receiving the Queen’s award, Lorraine Brown for receiving the Chronic Oedema Silver Nurse Award, and Nicole Faccio and the BLS Scientific Committee’s Fran Campbell for their Legs Matter.

Changemaker awards: congratulations too, to Cheryl White who passed her Leadership for Allied Health Professionals qualification with a distinction.

Yolande Borthwick was honoured with an invitation to a reception at Buckingham Palace hosted by Their Majesties The King and Queen, recognising community-based initiatives that raise awareness about cancer.

News & Views: Sharing Knowledge and Driving Practice

BLS’s quarterly publication, News & Views, continues to be a vital resource for healthcare professionals working in lymphoedema care. The newsletter supports members by sharing evidence-based guidance, updates on clinical practice, and insights into research and innovation in the field.

5

British Lymphology Society CIO Report of the Trustees for the year ended 31 March 2025

Key features include summaries of clinical enquiries, promotion of ongoing research studies, and the results of member surveys, helping to inform practice and support the development of new resources. News & Views also highlights updates to clinical pathways and best-practice guidance, as well as educational materials designed to strengthen professional development across the membership.

Through this publication, BLS fosters engagement and collaboration, ensuring that members’ insights and feedback help shape the society’s priorities and resources. It remains an essential tool in advancing knowledge, raising standards, and promoting excellence in lymphoedema care.

Voice, Advocacy & Partnerships

BLS continues to influence public policy and raise the profile of lymphoedema through strategic collaborations with organisations including NICE, Macmillan Cancer Support, the Pelvic Radiation Disease Association, Cancer Alliances, and TCST. These partnerships help shape standards of care, support research, and enhance awareness of lymphoedema across the healthcare system.

The charity continues to be recognised as a trusted source of expertise on lymphoedema, responding to press enquiries and contributing to national conversations about the condition. This year, we were pleased to provide accurate information to journalists and media outlets seeking specialist insight.

This year we also challenged misinformation, responding to inaccuracies on BBC Radio 2’s Jeremy Vine Show. By setting the record straight, we strengthened our reputation as the leading authority on lymphoedema and reinforced our commitment to clear, evidence-based information.

The BLS was invited to attend an event in support of the St George’s Lymphoedema Research Fund, which brought together a wide range of supporters, including high-profile figures such as Dame Judi Dench and Dame Joanna Lumley. Their presence helped shine a spotlight on lymphoedema research and the importance of continued investment.

The BLS maintains collaborative relationships with international lymphoedema associations and charities like ours, and shares best practice, new developments and information with our international colleagues.

Scientific Committee (BLSSC) Report 2024 - 25

Committee Members:

Emma Underwood (Chair) Fran Campbell (Vice Chair), Dr Ambreen Chohan, Prof Kristiana Gordon, Dr Garry Cooper, Dr Catherine O’Leary, Dr Catherine Mitchell, Patryk Gawrysiak, Preksha Vivekanandan (Honorary), Laura Henry (Honorary), Rebecca Elwell (Co-opted Conference Organiser).

During 2024/25 the Scientific Committee (SC) met online to continue to support the BLS Board with the overall aim of promoting research and service development in the field of lymphoedema in the UK.

Changes to membership:

In recognition of Rebecca Elwell’s continued support of the SC and the valuable role she plays as conference organiser it was agreed that she should be co-opted to the SC allowing her to remain on the SC indefinitely, whilst she continues in her conference liaison role. This has allowed an additional member to be recruited to the SC and it was agreed that this could be offered as either a full or honorary member position. We are pleased to have two honorary members on the SC which furthers the SC’s goal of nurturing early career researchers.

Key document updates:

The SC terms of reference have been reviewed and updated and the LDRG policy was reviewed and updated at the BLS Conference 2024.

6

British Lymphology Society CIO Report of the Trustees for the year ended 31 March 2025

The SC managed the abstract submission process and anonymous peer review selection for the 2024 conference, attracting 26 submissions. The marking criteria for abstract submissions has been reviewed to further ensure that the scientific content of the BLS conference is robust. The marking criteria and process for both the poster and oral presentations has been reviewed and streamlined.

Face to face poster presentations were introduced and were well received, allowing delegates the opportunity to meet presenters and discuss their work in more detail. The SC was responsible for scoring of both the oral and poster presentations at the conference and awarding best novice and experienced presenter awards.

The SC stand attracted a lot of footfall allowing the SC to encourage novice researchers, answer questions and promote SC initiatives.

The Case Report Competition

The case report competition winner was Susan Witt who will be supported to publish the case report in the Chronic Oedema Supplement.

The Lymphoedema Research Development Grant (LRDG)

We are pleased to announce that a team led by Susan Witt and including Professor Vaughan Keeley, Professor Neil Piller and Associate Professor Raoul van Loon following commendations from the SC on the application, have been awarded the £10,000 grant for a feasibility study ‘Measuring the direct impact of temperature on the lymphatic system and mechanical properties of skin’: a feasibility study (pending ethical approval).

Other contributions

Requests for the BLS to promote external research studies: the SC advises the Board. News & Views - SC members continue to contribute articles to the newsletter on a range of research and clinical evidence publication topics.

Clinical Queries: SC members have regularly provided or signposted to, scientific or clinical advice which are submitted to BLS. To widen the reach of this advice to the membership the queries and responses are now published in News and Views.

Clinical advisors to external bodies: SC members represent the BLS as clinical experts and advisors to bodies such as NICE when clinical reviews relevant to Lymphoedema are being conducted or when national/international guidelines are being created.

Contributing to specific BLS workstreams: Members of the SC have been part of specific working subgroups of the Board.

International networking and support: The SC chair advised the research lead for LEARN on documents and processes on the LRDG to enable development of a similar program with LEARN.

FINANCIAL REVIEW AND RESERVES POLICY

In 2025, the BLS generated £223k of income, broadly in line with 2024 (£226k). Our income streams comprised:

7

British Lymphology Society CIO Report of the Trustees for the year ended 31 March 2025

Expenditure in 2025 totalled £195k, which was £23k lower than 2024. The reduction was mainly due to the one-off £20k rebranding project in 2024, which was not repeated. Key points include:

Careful cost management has ensured that despite investment in strategic initiatives, our overall spend remains lower than the previous year. This provides a stable financial platform to support the BLS’s charitable mission going forward.

The reserves policy of the charity to maintain unrestricted funds which have not been designated for a specific use of twelve months’ expenditure. The policy ensures that reserves at this level will be sufficient so that in the event of a significant drop in funding, that the trustees will be able to continue the charity’s activities while consideration is given to ways in which additional funds may be raised. The twelve months’ expenditure level of reserves was achieved throughout the financial year.

2025-26

The BLS is entering an exciting year, building on recent achievements and marking 40 years since the society was established. Key priorities for 2025–26 include:

Thank You

We are deeply grateful to our passionate trustees, staff, corporate members, partners, and supporters. Your dedication, expertise, and commitment have enabled BLS to grow from strength to strength, advancing lymphoedema care, education, and research across the UK.

The policy of the charity to maintain unrestricted funds which have not been designated for a specific use of twelve months’ expenditure. The policy ensures that reserves at this level will be sufficient so that in the event of a significant drop in funding, that the trustees will be able to continue the charity’s activities while consideration is given to ways in which additional funds may be raised. The twelve months’ expenditure level of reserves was achieved throughout the financial year.

INDEPENDENT EXAMINER

Jonathan Bardolph ACA,FCCA & BFP has been re-appointed as independent examiner for the ensuing year.

17 Sep 2025 Approved by order of the board of trustees on………………………… and signed on its behalf by:

…………………………….

Lorraine Brown

8

British Lymphology Society CIO Independent Examiner's Report to the Trustees for the year ended 31 March 2025

I report to the trustees on my examination of the accounts of the above charity for the year ended 31 March 2025.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the charity's accounts as carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination which gives me cause to believe that in, any material respect:

  1. the accounting records were not kept in accordance with section 130 the Charities Act; or

  2. the accounts did not accord with the accounting records; or

  3. the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a "true and fair" view which is not a matter considered as part of an independent examination

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

J Bardolph

………….………. J Bardolph ACA, FCCA, BFP Independent Examiner

Accountably Ltd 1st Floor, Unit 12 Compass Point Ensign Way Hamble Southampton Hampshire SO31 4RA

18 Sep 2025

…………….……..

9

British Lymphology Society CIO Statement of Financial Activities for the year ended 31 March 2025

Notes
INCOMING RESOURCES
Incoming resources from generated funds
Voluntary income
2
Charitable activities
3
Investment income
4
Total incoming resources
RESOURCES EXPENDED
Charitable activities
5
Governance costs
6
Total resources expended
Net movement in funds
RECONCILIATION OF FUNDS
Total funds brought forward
10
TOTAL FUNDS CARRIED FORWARD
10
NET INCOMING RESOURCES and net
income for the year		 2025
Unrestricted
fund
Restricted
fund
Total funds
£
£
£
66,311
-
66,311
146,133
-
146,133
9,649
560
10,209
222,093
560
222,653
190,758
-
190,758
4,762
-
4,762
195,520
-
195,520
26,573
560
27,133
26,573
560
27,133
267,063
22,660
289,723
293,636
23,220
316,856		 2024
Total funds
£
58,283
161,624
6,195
226,102
212,271
5,775
218,046
8,056
8,056
281,667
289,723

The Statement of Financial Activities includes all gains and losses in the year and therefore a statement of total recognised gains and losses has not been prepared.

All of the above amounts relate to continuing activities.

The notes form part of these financial statements.

10

British Lymphology Society CIO
Balance Sheet
as at 31 March 2025
Notes
FIXED ASSETS
Intangible fixed assets
7
CURRENT ASSETS
Debtors
8
Cash at bank
CREDITORS
Amounts falling due within one
year
9
NET CURRENT ASSETS
NET ASSETS
FUNDS
10
Unrestricted funds:
Restricted funds
TOTAL FUNDS		 2025
Total funds
£
23,910
93,962
312,903
406,865
(113,919)
292,946
316,856
293,636
23,220
316,856
17 Sep 2025		 2024
Total funds
£
-
49,021
379,229
428,250
(138,527)
289,723
289,723
267,063
22,660
289,723

The financial statements were approved by the Board of Trustees on ……………………..…... and were signed on its behalf by:

Yolande Borthwick

P Hooper-Smith

………………………………… ……………………………..

Chairperson - Yolande Borthwick

Treasurer - Peter Hooper-Smith

The notes form part of these financial statements.

11

British Lymphology Society CIO Notes to the Financial Statements for the year ended 31 March 2025

1 ACCOUNTING POLICIES

(a) Basis of preparation of the accounts

The accounts have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to the accounts. The accounts have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) effective January 2019.

(b) Funds

General funds represent the funds of the charity that are not subject to any restrictions regarding their use and are available for application for general purposes. Funds designated for a particular purpose by the charity are also unrestricted. Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

(c) Incoming resources

Donations, legacies and other forms of voluntary income are recognised as incoming resources when receivable, except in so far as they are incapable of financial measurement.

Trading income is shown net of related expenses as this better reflects the contribution of these activities to the charity.

Income tax recoverable in relation to donations received under Gift Aid is recognised at the time of the donation.

(d) Resources expended

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity. Governance costs are those associated with the governance arrangements of the charity.

(e) Intangible fixed assets

Depreciation is provided so as to write off the cost of the asset, less its estimated residual value over the useful economic life of that asset, as follows:

Website development 20% straight line

(f) Taxation

The charity is exempt from corporation tax on its charitable activities.

2
VOLUNTARY INCOME
Membership subscriptions		 Unrestricted
funds
£
66,311
66,311		 Restricted
funds
£
-
-		 Total funds
2025
£
66,311
66,311		 Total funds
2024
£
58,283
58,283

12

British Lymphology Society CIO Notes to the Financial Statements for the year ended 31 March 2025

3
CHARITABLE ACTIVITIES
Conference
Advertising and other services
4
INVESTMENT INCOME
Interest receivable
5
EXPENDITURE - Charitable activities
Office and administration costs
Website, computer and internet costs
Newsletter
Conference
Promotional items and surveys
Wages and expenses
6
EXPENDITURE - Governance costs
Book-keeping
Independent examiner
Insurance
Committee meetings
Exchange differences		 Unrestricted
funds
£
135,082
11,051
146,133
Unrestricted
funds
£
9,649
Unrestricted
funds
£
62,405
2,444
3,793
89,647
3,706
28,763
190,758
Unrestricted
funds
£
569
1,800
1,036
1,321
36
4,762		 Restricted
funds
£
-
-
-
Restricted
funds
£
560
Restricted
funds
£
-
-
-
-
-
-
-
Restricted
funds
£
-
-
-
-
-
-		 Total funds
2025
£
135,082
11,051
146,133
Total funds
2025
£
10,209
Total funds
2025
£
62,405
2,444
3,793
89,647
3,706
28,763
190,758
Total funds
2025
£
569
1,800
1,036
1,321
36
4,762		 Total funds
2024
£
147,588
14,036
161,624
Total funds
2024
£
6,195
Total funds
2024
£
52,871
5,282
5,200
98,868
25,620
24,430
212,271
Total funds
2024
£
499
1,740
1,359
2,025
152
5,775

13

British Lymphology Society CIO Notes to the Financial Statements for the year ended 31 March 2025

7 INTANGIBLE FIXED ASSETS

Cost
At 1 April 2024
Additions
Disposals
At 31 March 2025
Amortisation
At 1 April 2024
Charge for the year
On disposals
At 31 March 2025
Net book value
At 31 March 2025
At 31 March 2024
 The trustees have decided not to amortise in this period as development costs ar
8
DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
Trade debtors
Other debtors
9
CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
Trade creditors
Deferred income
Accrued charges		 2025
£
-
23,910
-
23,910
-
-
-
-
23,910
-
e ongoing.
2025
£
66,935
27,027
93,962
2025
£
108
109,615
4,196
113,919		 Total
£
-
23,910
-
23,910
-
-
-
-
23,910
-
2024
£
27,245
21,776
49,021
2024
£
9,607
124,874
4,046
138,527

10 MOVEMENT ON UNRESTRICTED AND RESTRICTED FUNDS

Unrestricted
General fund
Restricted fund:
Scientific research		 Balance at 1
April
2024
£
267,063
22,660
289,723		 Incoming
resources
£
222,093
560
222,653		 Outgoing
resources
£
(195,520)
-
(195,520)		 Transfers
between
funds
£
-
-
-		 Balance at
31 March
2025
£
293,636
23,220
316,856

14

British Lymphology Society CIO Notes to the Financial Statements for the year ended 31 March 2025

11 ANALYSIS OF NET ASSETS BETWEEN FUNDS
Unrestricted:
General fund
Restricted:
Scientific research		 Intangible
fixed assets
£
23,910
-
23,910		 Net current
assets
£
269,726
23,220
292,946		 Total
£
293,636
23,220
316,856

12 OTHER BENEFITS RECEIVED BY THE CHARITY

We are grateful to our corporate members for their generosity and their support in the 2024 conference. In addition, thank you to all who sponsor us in formal and informal ways.

13 TRUSTEES REMUNERATION AND EXPENSES

The following trustees received reimbursement of expenses during the year:

£
K Riches 69
M Sneddon 599
R Hutton 404
R Elwell 223
L Brown 611
C White 2,105
Y Borthwick 760
P Hooper-Smith 535
E Underwood 608

No trustee nor anyone connected with them received any remuneration during the period in respect of their services as trustees.

15

Issuer

Accountably Ltd

Document generated Wed, 17th Sep 2025 15:56:02 BST

Document fingerprint 7278fab069e2d558b5545bc6f22438e0

Parties involved with this document

Document processed

Party + Fingerprint

Wed, 17th Sep 2025 15:58:44 BST Wed, 17th Sep 2025 16:13:08 BST Wed, 17th Sep 2025 20:24:42 BST

Mr Peter Hooper-Smith - Signer (c8a7630d7bf9d105c08373b9bc3c535a) Mrs Lorraine Brown - Signer (a272e3b0a92a3521f3a96a136c921385) Mrs Yolande Borthwick - Signer (cc3ebb36a8722eca10098efe2b804e99)

Audit history log

Date

Action

Wed, 17th Sep 2025 15:56:02 BST Wed, 17th Sep 2025 15:56:02 BST Wed, 17th Sep 2025 15:56:02 BST

Wed, 17th Sep 2025 15:56:02 BST Wed, 17th Sep 2025 15:56:02 BST Wed, 17th Sep 2025 15:56:02 BST

Wed, 17th Sep 2025 15:56:10 BST Wed, 17th Sep 2025 15:56:10 BST Wed, 17th Sep 2025 15:56:11 BST Wed, 17th Sep 2025 15:57:40 BST Wed, 17th Sep 2025 15:58:44 BST Wed, 17th Sep 2025 15:58:44 BST Wed, 17th Sep 2025 15:58:44 BST Wed, 17th Sep 2025 16:12:14 BST Wed, 17th Sep 2025 16:12:20 BST Wed, 17th Sep 2025 16:13:08 BST

Envelope generated with fingerprint ced1d75e6efad90de2fbf7decb7fd614 (35.176.231.177) Document generated with fingerprint 7278fab069e2d558b5545bc6f22438e0. (35.176.231.177) Mr Peter Hooper-Smith has been assigned to this envelope. (35.176.231.177) Mrs Lorraine Brown has been assigned to this envelope. (35.176.231.177) Mrs Yolande Borthwick has been assigned to this envelope. (35.176.231.177) Envelope has been set to automatically remind the active signer every 2 day(s). (35.176.231.177) Envelope generated Sent the envelope to Mr Peter Hooper-Smith for signing Document emailed to party email

Mr Peter Hooper-Smith viewed the envelope (31.94.12.94) Mr Peter Hooper-Smith signed the envelope (31.94.12.94) Sent the envelope to Mrs Lorraine Brown for signing (31.94.12.94) Document emailed to party email

Mrs Lorraine Brown viewed the envelope (208.127.199.47) Mrs Lorraine Brown viewed the envelope (62.252.191.196) Mrs Lorraine Brown signed the envelope (208.127.199.47)

Wed, 17th Sep 2025 16:13:09 BST Wed, 17th Sep 2025 16:13:09 BST Wed, 17th Sep 2025 20:23:09 BST Wed, 17th Sep 2025 20:23:22 BST Wed, 17th Sep 2025 20:24:42 BST Wed, 17th Sep 2025 20:24:42 BST

Sent the envelope to Mrs Yolande Borthwick for signing (208.127.199.47) Document emailed to party email Mrs Yolande Borthwick viewed the envelope (86.129.120.64) Mrs Yolande Borthwick viewed the envelope (62.252.232.5) Mrs Yolande Borthwick signed the envelope (86.129.120.64) This envelope has been signed by all parties (86.129.120.64)

Issuer

Accountably Ltd

Document generated Thu, 18th Sep 2025 11:04:11 BST

Document fingerprint 4f643267cd15d746c92ec64818ea3098

Parties involved with this document

Document processed

Party + Fingerprint

Thu, 18th Sep 2025 11:18:55 BST Thu, 18th Sep 2025 11:18:55 BST

Jonathan Bardolph - Signer (06f1d2141b79c190f86752bc606ec949) Kirsty Lovett - Copied In (d220247e0e014297174fb0b6b47f8dd7)

Audit history log

Date

Action

Thu, 18th Sep 2025 11:04:11 BST Thu, 18th Sep 2025 11:04:11 BST

Thu, 18th Sep 2025 11:04:11 BST Thu, 18th Sep 2025 11:04:11 BST Thu, 18th Sep 2025 11:04:11 BST

Thu, 18th Sep 2025 11:06:28 BST Thu, 18th Sep 2025 11:06:28 BST Thu, 18th Sep 2025 11:06:30 BST Thu, 18th Sep 2025 11:18:27 BST Thu, 18th Sep 2025 11:18:55 BST Thu, 18th Sep 2025 11:18:56 BST Thu, 18th Sep 2025 11:18:56 BST Thu, 18th Sep 2025 11:18:56 BST

Envelope generated with fingerprint 71c6b2f8884b9fa227d19356d8225333 (35.176.231.177)

Document generated with fingerprint 4f643267cd15d746c92ec64818ea3098. (35.176.231.177) Jonathan Bardolph has been assigned to this envelope. (35.176.231.177) Kirsty Lovett has been assigned to this envelope. (35.176.231.177) Envelope has been set to automatically remind the active signer every 1 day(s). (35.176.231.177)

Envelope generated Sent the envelope to Jonathan Bardolph for signing Document emailed to party email

Jonathan Bardolph viewed the envelope (51.195.204.129) Jonathan Bardolph signed the envelope (51.195.204.129) Sent the envelope to Kirsty Lovett for signing (51.195.204.129) This envelope has been signed by all parties (51.195.204.129) Document emailed to party email